GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2019
    In:  Journal of Clinical Oncology Vol. 37, No. 15_suppl ( 2019-05-20), p. e18297-e18297
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, No. 15_suppl ( 2019-05-20), p. e18297-e18297
    Abstract: e18297 Background: Between April 1, 2014 and October 17, 2018, access to cannabis for medical purposes was regulated by Health Canada. Surveys have demonstrated that cancer patients use cannabis to manage symptoms and side effects. However, medical cannabis utilization patterns in cancer patients under Health Canada’s regulatory framework have not been well-described. We aimed to determine the proportion of cancer patients who used medical cannabis, timing of use in relation to cancer treatment and sociodemographic factors predicting use in a large Canadian province. Methods: The Alberta Cancer Registry was used to identify all patients age ≥ 18 diagnosed with invasive cancer in the province from April 01, 2014 to December 31, 2016. These cases were linked to records from the College of Physicians and Surgeons of Alberta database which collects data on patients who received authorization to access medical cannabis as well as on physicians that provided the authorization. Authorization was used as a surrogate for medical cannabis utilization. Univariate and multivariate logistic regression models were constructed to determine factors associated with medical cannabis utilization. Results: We identified 41,889 patients between April 1, 2014 and December 31, 2016. Median age at cancer diagnosis was 65 and 50% were female. Among these patients, 1,070 (2.5%) used medical cannabis. Of these patients, 541 (51%) used medical cannabis within 1 year of diagnosis, 248 (52%) within one year of the start of systemic therapy and 128 (41%) within one year of the start of radiation therapy. On multivariate analysis, patients aged 18-29 (OR 12.4, 95% CI 7.8-19.7) and those receiving systemic therapy (OR 2.0, 95% CI 1.7-2.4) were more likely to use medical cannabis (p 〈 0.001). There were 171 unique physicians who authorized medical cannabis of which only 3.5% (6/171) were oncologists. Conclusions: A small proportion of cancer patients used medical cannabis under Health Canada’s regulatory framework. Utilization was associated with a cancer diagnosis and receiving treatment. Younger patients and those undergoing systemic treatment were predictors of medical cannabis use. Further study is required to understand utilization patterns after cannabis legalization and how to incorporate these findings into patient-centered cancer care.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2019
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 36, No. 34_suppl ( 2018-12-01), p. 88-88
    Abstract: 88 Background: Despite known benefits, cancer care systems struggle to provide early, integrated palliative care (PC). Previously, we identified barriers to providing early PC as perceived by gastrointestinal oncology clinicians in Alberta, Canada (top barrier: time/competing priorities). Here, we expand on the previous study to better understand barriers to early PC for clinicians working with all tumor groups across Alberta. Methods: A 33-item survey was emailed to oncology clinicians in Alberta between November 2017 - January 2018. Questions were informed by Michie’s Theoretical Domains Framework (TDF) and Behaviour Change Wheel (BCW) and queried (a) providing PC in oncology clinics, (b) referral to specialist PC consultation, and (c) working with PC consultants and homecare. Results: Respondents (n = 268) were nurses (42%), physicians (25%), and allied health professionals (20%). Barriers most frequently identified were "patients’ negative perceptions of PC” (68%), “my limited time/competing priorities” (66%), and "capability to manage patients’", social (65%) and spiritual (63%) concerns. These factors map to all three BCW domains: motivation, opportunity, and capability. In contrast, least frequently identified barriers were in clinician’s own motivation, e.g. perceived benefits of PC. There were few significant differences in response by tumor group or profession (χ 2 test, responses coded: disagree [1-3], neutral [4] , agree [5-7]). Most notably, tumor groups differed in their perception that “the criteria for PC services are too restrictive” (p = 0.003), while nurses and allied staff reported that patients’ negative perception of PC is a barrier more frequently than physicians (p = 0.003). Conclusions: Surveying across clinicians and tumor groups using Michie’s TDF/BCW revealed that the challenges to an early integrated PC approach include all three sources of behavior, though not equally for all clinicians. Determining this has allowed us to tailor multifaceted interventions, e.g. tip sheets to enhance capability, re-framing PC with patients, and earlier secondary PC nursing access, to enhance clinicians use and patients benefit from an early PC approach.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2018
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, No. 27_suppl ( 2019-09-20), p. 207-207
    Abstract: 207 Background: The “Living with Colorectal Cancer study” seeks to characterize the experiences of patients diagnosed with advanced colorectal cancer to inform care improvements. Here we describe our experiences recruiting patients and collecting patient reported outcome measures (PROMs). Methods: Eligible patients were identified by oncologists in Alberta, Canada’s two tertiary cancer centres and approached for consent to participate during routine appointments. Following baseline surveys, participants were given a choice of completing monthly surveys via email, phone, post, or in person. We purposively chose previously validated surveys already in use provincially, including EQ-5D-5L and Putting Patients First. We endeavoured to include non-English speaking participants by providing translated study materials and interpretation. Results: In one year of recruitment, 88 patients were enrolled. Edmonton, Alberta’s patient recruitment (N = 62) is double that of Calgary, Alberta (N = 26), despite similar population sizes. In Calgary and Edmonton, 81% and 56% of participants chose email-based PROMs surveys, respectively. The current missing survey rate is 12% (i.e. surveys not completed per month). Forty-eight participants (55%) completed ≥6 sets of monthly PROMs data; 26 (30%) transferred “off study” (61% of which died). Several participants expressed the desire to describe their experiences beyond what the surveys could accommodate. Despite language accommodation, all participants chose to complete surveys in English; however, 21% reported speaking another language daily. Conclusions: It is challenging but possible to engage and retain patients with advanced cancer in research focused on PROMs. Speaking with patients face-to-face in cancer clinics increased the burden on healthcare providers (i.e. clinic flow and time spent with patients), but appears to be a practical and appropriate way to recruit participants. Offering multiple methods of communication allowed patients to participate in a manner most practical for their lifestyle and did not impact PROMs collection. Clinical trial information: NCT03572101.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2019
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, No. 15_suppl ( 2019-05-20), p. 6614-6614
    Abstract: 6614 Background: More patients are experiencing aggressive end-of-life (EOL) care. This is concerning as aggressive EOL care, on a population level, is associated with poor quality care. Specialist palliative care (PC) has been shown to help relieve EOL symptoms, improve patient quality of life, and reduce aggressive EOL care. This study aimed to estimate the impact of the timing of specialist PC, specifically PC delivered at least 3 months prior to death, on a colorectal cancer (CRC) patient’s risk experiencing aggressive care in the last 30 days of life. Methods: A population-based retrospective cohort study of adult patients who died from CRC in Alberta, Canada from 2011-2015. The Alberta Cancer Registry was used to identify the cohort, which was linked to healthcare resource use data in local, provincial, and national databases. Individuals who died 〈 30 days from CRC diagnosis were excluded. Patients who accessed any of the provinces specialist PC services were deemed exposed to specialist PC (includes PC consult team, intensive PC unit, palliative home care, hospice). Aggressive EOL care was defined as having experienced at least one of: hospital death, 〉 1 emergency department visit, 〉 1 hospital admission, 〉 14 days of hospitalization, ≥1 intensive care unit admission, ≥1 new chemotherapy program (or any treatment in the last 14 days of life). Logistic regression was used to model factors (specialist PC timing and clinical characteristics) associated with aggressive EOL care. Results: The cohort comprised 2979 patients. Most patients received specialist PC before death (58%); 60% had ≥1 indicator of aggressive EOL care. Relative to patients who received specialist PC 〉 3 months before death, patients who received specialist PC 〈 3 months before death were 1.5 times more likely to experience aggressive EOL care (CI: 1.2-1.9). Patients who received no specialist PC were 2.1 times more likely to experience aggressive EOL care (CI: 1.7-2.8). Short disease duration ( 〈 1 year from diagnosis to death), younger age at death, living in a rural area, and male sex, were also associated with higher odds of experiencing aggressive EOL care. Conclusions: Specialist PC delivered 〉 3 months before death reduces a CRC patient’s risk of experiencing aggressive EOL care over PC delivered 〈 3 months before death.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2019
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Canadian Urological Association Journal ; 2018
    In:  Canadian Urological Association Journal Vol. 12, No. 7 ( 2018-03-15), p. E314-7
    In: Canadian Urological Association Journal, Canadian Urological Association Journal, Vol. 12, No. 7 ( 2018-03-15), p. E314-7
    Abstract: Introduction: Treatment decisions in localized prostate cancer are complicated by the available choices. A rapid-access cancer clinic (RAC) has been unique to Calgary, AB, since 2007. This RAC offers multidisciplinary prostate cancer education by a urologist, medical oncologist, and radiation oncologist. It is hypothesized that treatment utilization data from decisions taken at RAC may serve to benchmark the appropriateness of treatment decisions on a population level.Methods: Records of patients with clinically localized prostate cancer in Alberta between October 1, 2007 and September 30, 2009 were reviewed with ethics approval. Records were linked to the Alberta Cancer Registry database. Clinical, treatment, and health services characteristics pertaining to patients attending RAC were compared to the general population. The primary endpoint was utilization rates of each initial treatment.Results: During this two-year period, 2838 patients were diagnosed with localized prostate cancer; 375 attended RAC. The utilization rates among RAC patients vs. the whole Alberta population were: prostatectomy 60.3% (95% confidence interval [CI] 55.3–65.2) vs. 48.0% (95% CI 47.1‒50.7; χ2 p 〈 0.001); active surveillance 16.0% (95% CI 12.3‒19.7%) vs. 13.5% (95% CI 12.2‒15.8; χ2 p=0.214); radiotherapy 11.7% (95% CI 8.5‒15.0) vs. 18.0% (95% CI 16.9‒20.5; χ2 p=0.002); and hormone therapy 8.0% (95% CI 5.2‒10.8) vs. 17.4% (95% CI 16.1‒18.9; χ2 p 〈 0.001).Conclusions: A specialized clinic for localized prostate cancer may be associated with a higher likelihood of receiving surgery or active surveillance as initial treatment compared to the prostate cancer population in Alberta.
    Type of Medium: Online Resource
    ISSN: 1920-1214 , 1911-6470
    Language: Unknown
    Publisher: Canadian Urological Association Journal
    Publication Date: 2018
    detail.hit.zdb_id: 2431403-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Elsevier BV ; 2020
    In:  Journal of Pain and Symptom Management Vol. 59, No. 6 ( 2020-06), p. 1223-1231
    In: Journal of Pain and Symptom Management, Elsevier BV, Vol. 59, No. 6 ( 2020-06), p. 1223-1231
    Type of Medium: Online Resource
    ISSN: 0885-3924
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2020
    detail.hit.zdb_id: 1500639-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: The Lancet Oncology, Elsevier BV, Vol. 22, No. 7 ( 2021-07), p. 1023-1033
    Type of Medium: Online Resource
    ISSN: 1470-2045
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 2049730-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    Elsevier BV ; 2016
    In:  Radiotherapy and Oncology Vol. 120 ( 2016-09), p. S62-
    In: Radiotherapy and Oncology, Elsevier BV, Vol. 120 ( 2016-09), p. S62-
    Type of Medium: Online Resource
    ISSN: 0167-8140
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2016
    detail.hit.zdb_id: 1500707-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Radiotherapy and Oncology, Elsevier BV, Vol. 150 ( 2020-09), p. S26-
    Type of Medium: Online Resource
    ISSN: 0167-8140
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2020
    detail.hit.zdb_id: 1500707-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Supportive Care in Cancer, Springer Science and Business Media LLC, Vol. 23, No. 9 ( 2015-9), p. 2731-2737
    Type of Medium: Online Resource
    ISSN: 0941-4355 , 1433-7339
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2015
    detail.hit.zdb_id: 1463166-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...